A prospective observational safety study of patients with BRAF ^{V 600} -mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)

Funding sources: This study was sponsored by F. Hoffmann‐La Roche Ltd. Medical writing assistance was provided by Lucy Smithers (ApotheCom, San Francisco, CA, U.S.A.), and was funded by F. Hoffmann‐La Roche Ltd. The study sponsor was involved in the study design and the decision to publish. Data collection and analysis were performed by UBC, a contract research organization. The manuscript was prepared by the authors. Conflicts of interest: P.G.C. has received speakers’ honoraria from Novartis and Merck Sharp & Dohme, and has participated in advisory boards for Bristol‐Myers Squibb, Celgene, Incyte, Novartis, Pierre Fabre and Roche. P.T. has received speakers’ honoraria from Bristol‐Myers Squibb, Novartis and Roche, and consultants’ honoraria from Bristol‐Myers Squibb, Merck, Novartis and Roche. A.J.t.T. has participated in advisory boards for Roche. R.H. has received grants and speakers’ honoraria from Bristol‐Myers Squibb, GlaxoSmithKline, Novartis and Roche, and has participated in advisory boards for Amgen, Bristol‐Myers Squibb, GlaxoSmithKline, Novartis and Roche. R.J. has participated in advisory boards for Amgen and Merck Serono. M.M. has participated in advisory boards for Bristol‐Myers Squibb, has received grants and travel support from Bristol‐Myers Squibb, Novartis and Roche, and has received grants from Merck. D.D. has received honoraria from Amgen, Novartis and Roche and has received nonfinancial support from Amgen, Merck Sharp & Dohme, Novartis, Pierre Fabre and Roche. R.M., M.B.‐M. and K.F. have no conflicts of interest to declare. M.L.G.M., G.R.G., J.J.H., N.S. and D.C. are employees of, and own stock options in, Genentech Inc. P.R. has received a research grant from Bristol‐Myers Squibb, and participated in advisory boards for Amgen, Bayer, Bristol‐Myers Squibb, GlaxoSmithKline, Merck Sharp & Dohme and Novartis.